Oncimmune buoyed by US distribution deal for blood tests

(Sharecast News) - Oncimmune Holdings made gains on Thursday after it entered an agreement with America's Choice Provider Network to expand access to its EarlyCDT-Lung and EarlyCDT-Liver blood tests.The network is an independent, multi-specialty provider network accessed by over 1,700 payers, to which more than 28m Americans and 0.75m international lives have access.Marco Casarin, general manager of Oncimmune USA, said: "Our collaboration with America's Choice Provider Network is one of several payor and provider agreements we have recently finalised to ensure as many people as possible in the US are able to use our EarlyCDT tests to facilitate earlier diagnoses."EarlyCDT-Lung is used by clinicians to assess lung cancer risk in high-risk patients who have an indeterminate pulmonary nodule and is highly specific in detecting lung cancer, making it complementary to the high sensitivity but poor specificity of CT scanning.Meanwhile, EarlyCDT-Liver aids in the detection and confirmation of hepatocellular carcinoma (HCC, liver cancer), in association with imaging, in high-risk patients with liver lesions of all sizes."Especially in lung cancer-with nearly 1.6m Americans having an incidentally detected nodule on the lung-a positive EarlyCDT-Lung outcome enables quicker clinician intervention and better patient outcomes," said Casarin.Oncimmune's shares were up 9.79% at 129.00p at 1628 GMT.